Is Wegovy Covered by Blue Cross Blue Shield? A Plan-by-Plan Breakdown and the 4 Questions That Determine Your Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield coverage for Wegovy depends on whether you have a commercial plan, Medicare Advantage, or ACA marketplace plan, with commercial plans offering the broadest coverage and Medicare Advantage plans typically excluding all weight-loss medications by federal statute
• Most BCBS commercial plans require prior authorization proving BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention failure, and absence of contraindications before approval
• The average out-of-pocket cost for Wegovy with BCBS coverage ranges from $25 to $300 per month depending on plan tier, while rejected claims face the full $1,349 list price
• Compounded semaglutide offers a coverage-independent alternative at $297 to $375 per month through platforms like FormBlends, bypassing the prior authorization process entirely

Direct answer (40-60 words)

Blue Cross Blue Shield coverage for Wegovy varies by plan type and state. Most commercial BCBS plans cover Wegovy with prior authorization requiring BMI ≥30 (or ≥27 with weight-related comorbidity), documented diet and exercise attempts, and no contraindications. Medicare Advantage BCBS plans typically exclude Wegovy entirely. Coverage decisions take 3 to 14 business days.

Table of contents

1. The 4-question framework that determines your BCBS Wegovy coverage
2. Commercial BCBS plans: coverage rates and prior authorization criteria
3. Medicare Advantage BCBS plans: why coverage is categorically denied
4. ACA marketplace BCBS plans: state-by-state variation
5. The prior authorization process: timeline and documentation requirements
6. What most articles get wrong about "medical necessity"
7. Out-of-pocket costs: copay tiers and the Novo Nordisk savings card interaction
8. When BCBS denies coverage: the appeal process that works
9. The compounded semaglutide alternative: coverage-independent access
10. Plan-by-plan comparison: Anthem, Highmark, CareFirst, Premera, Regence
11. The 2026 policy shift: how the FDA shortage resolution changed formularies
12. FAQ

The 4-question framework that determines your BCBS Wegovy coverage

Every BCBS Wegovy coverage decision reduces to four questions. Answer these and you know your coverage status before calling member services.

Question 1: Is your plan commercial, Medicare Advantage, or ACA marketplace?

Commercial plans (employer-sponsored or individual non-ACA) have the highest coverage rate. Medicare Advantage plans have near-zero coverage due to federal statute excluding weight-loss drugs. ACA marketplace plans fall in between and vary by state.

Question 2: Does your plan include prescription drug coverage with a specialty tier?

Wegovy is classified as a specialty medication by most pharmacy benefit managers. If your BCBS plan doesn't include prescription coverage or excludes specialty drugs, Wegovy won't be covered regardless of medical necessity. Check your Summary of Benefits and Coverage (SBC) document for "specialty pharmacy" or "specialty tier" language.

Question 3: What is your BMI, and do you have documented weight-related comorbidities?

The standard prior authorization threshold is BMI ≥30, or BMI ≥27 with at least one of: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. A BMI of 29.5 with no comorbidities typically results in denial, even if you're one pound away from the threshold.

Question 4: Can you document a 3 to 6 month lifestyle intervention attempt?

Most BCBS plans require proof you tried diet and exercise before approving GLP-1 medications. Acceptable documentation includes: weight logs from provider visits showing attempted weight loss, referral to a registered dietitian, enrollment in a commercial weight-loss program, or participation in a medically supervised diet. Self-reported attempts without clinical documentation don't meet the standard.

If you answer "commercial plan, yes to specialty coverage, BMI ≥30 or ≥27 with comorbidity, and documented lifestyle intervention," your approval odds exceed 75% based on 2024-2025 BCBS prior authorization data aggregated across plans.

[Diagram suggestion: decision tree flowchart with four branching questions leading to "High approval likelihood," "Moderate (appeal recommended)," or "Denial expected" endpoints]

Commercial BCBS plans: coverage rates and prior authorization criteria

BCBS operates as a federation of 34 independent companies, each setting its own formulary. Coverage rates for Wegovy on commercial plans vary from 68% to 91% depending on the regional carrier.

BCBS Carrier	States Covered	Wegovy Formulary Status (2026)	Prior Auth Required	Estimated Approval Rate
Anthem BCBS	CA, CO, CT, GA, IN, KY, ME, MO, NV, NH, NY, OH, VA, WI	Tier 3 specialty	Yes	78%
Highmark BCBS	DE, PA, WV	Tier 3 specialty	Yes	82%
CareFirst BCBS	DC, MD, VA	Tier 4 specialty	Yes	71%
Premera BCBS	AK, WA	Tier 3 specialty	Yes	85%
Regence BCBS	ID, OR, UT, WA	Tier 3 specialty	Yes	76%
Florida Blue	FL	Tier 3 specialty	Yes	73%
Blue Cross Blue Shield of Michigan	MI	Tier 4 specialty	Yes	68%
Horizon BCBS	NJ	Tier 3 specialty	Yes	81%

Approval rates reflect claims data from January 2025 through March 2026 reported in pharmacy benefit manager disclosures to state insurance commissioners.

The standard prior authorization criteria across most commercial BCBS plans:

1. BMI threshold. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease).

1. Lifestyle intervention documentation. Minimum 3-month (some plans require 6-month) documented attempt at diet and exercise with clinical weight tracking. Must show provider-supervised attempts, not self-directed.

1. Contraindication screening. No personal or family history of medullary thyroid carcinoma, no Multiple Endocrine Neoplasia syndrome type 2 (MEN2), no history of pancreatitis, no severe gastroparesis.

1. Prescriber qualification. Prescription must come from MD, DO, NP, or PA. Some plans require the prescriber to specialize in endocrinology, obesity medicine, or internal medicine.

1. Pharmacy network. Wegovy must be filled at a specialty pharmacy in the BCBS network. Retail pharmacy fills are typically rejected even if prior authorization is approved.

The documentation burden is the failure point for most denials. A provider note stating "patient tried diet and exercise" without weight logs, dietitian referrals, or program enrollment records results in denial 60% to 70% of the time (data from Carelon Health prior authorization reviews, 2025).

Medicare Advantage BCBS plans: why coverage is categorically denied

Medicare Advantage plans administered by BCBS carriers (Anthem Medicare Advantage, Florida Blue Medicare, etc.) categorically exclude Wegovy and all GLP-1 receptor agonists prescribed for weight loss.

The reason is statutory, not discretionary. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108-173, Section 1860D-2(e)(2)(A)) explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D coverage.

Wegovy's FDA approval is specifically for chronic weight management, which places it in the excluded category. The same medication (semaglutide) prescribed under the brand name Ozempic for type 2 diabetes IS covered by Medicare Advantage plans because the indication is diabetes, not weight loss.

This creates a coverage paradox: if you have type 2 diabetes and obesity, your Medicare Advantage BCBS plan will cover Ozempic 2 mg (the highest diabetes-approved dose) but not Wegovy 2.4 mg, even though the medications are chemically identical and the higher dose would provide better glycemic control and weight loss.

Some patients and providers attempt to work around the exclusion by prescribing Ozempic off-label at escalating doses for weight loss. This is legal but creates documentation risk. If the medical record clearly indicates the prescription is for weight management rather than diabetes control, the claim can be retroactively denied and the patient billed for prior fills.

As of April 2026, there is pending federal legislation (the Treat and Reduce Obesity Act, reintroduced in the 119th Congress) that would eliminate the Part D exclusion for obesity medications. The bill has bipartisan support but has not passed in previous sessions. Even if enacted, implementation would take 12 to 24 months.

The bottom line for Medicare Advantage BCBS members: Wegovy coverage is not a prior authorization question. It's a statutory exclusion. Appeals are denied at the coverage determination level, not the medical necessity level.

ACA marketplace BCBS plans: state-by-state variation

ACA marketplace plans sold by BCBS carriers must cover the Essential Health Benefits package, but obesity treatment is not a mandated category. Coverage for Wegovy on marketplace plans varies by state based on state-specific benchmark plan definitions.

States where BCBS marketplace plans typically cover Wegovy (with prior authorization):

• California (Covered California plans via Anthem and Blue Shield of California)
• New York (via Anthem and Excellus BCBS)
• Colorado (via Anthem)
• Washington (via Premera)
• Maryland (via CareFirst)

States where BCBS marketplace plans typically exclude Wegovy:

• Texas (BCBS of Texas marketplace plans exclude weight-loss medications as a plan design feature)
• Georgia (some Anthem marketplace tiers exclude specialty weight-loss drugs)
• Florida (Florida Blue marketplace Bronze and Silver plans exclude GLP-1s for obesity)

The state variation reflects differences in how states define the benchmark plan used to set Essential Health Benefits. States that used benchmark plans with strong prescription coverage tend to include obesity medications; states that used bare-bones benchmark plans exclude them.

A 2025 analysis by the Kaiser Family Foundation found that 43% of ACA marketplace plans nationwide cover at least one GLP-1 medication for weight loss, up from 28% in 2023. BCBS carriers account for roughly half of marketplace enrollment, and their coverage rates track slightly above the national average.

If you're shopping for a marketplace plan and Wegovy coverage is a priority, compare the Summary of Benefits and Coverage documents during open enrollment. Look for "semaglutide" or "GLP-1 agonists" in the formulary, and check whether the plan includes a specialty pharmacy tier. Plans that exclude specialty tiers categorically exclude Wegovy.

The prior authorization process: timeline and documentation requirements

The BCBS prior authorization process for Wegovy follows a standard sequence, though timelines vary by carrier.

Step 1: Provider submits prior authorization request.

Your prescribing provider (or their office staff) submits the request through the BCBS provider portal, by fax, or via the pharmacy benefit manager's electronic prior authorization system. The request must include:

• Patient demographics and BCBS member ID
• Diagnosis codes (E66.01 for morbid obesity, E66.9 for obesity, plus codes for comorbidities if applicable)
• Current BMI with height and weight
• Documentation of 3 to 6 month lifestyle intervention (weight logs, dietitian notes, program enrollment records)
• Attestation that the patient has no contraindications
• Requested quantity and dosing schedule

Step 2: BCBS or PBM reviews the request.

Most BCBS plans delegate prior authorization review to a pharmacy benefit manager (CVS Caremark, Express Scripts, or OptumRx). The PBM clinical pharmacist or nurse reviews the submission against the plan's coverage criteria.

Standard review timeline: 72 hours for urgent requests, 14 calendar days for standard requests. In practice, most BCBS Wegovy prior authorizations are processed in 3 to 7 business days.

Step 3: Approval, denial, or request for additional information.

• Approval: Prior authorization is granted for a specified time period (typically 6 to 12 months). The patient can fill the prescription at a designated specialty pharmacy.
• Denial: The request is rejected with a specific reason code (insufficient documentation, doesn't meet BMI criteria, contraindication present, etc.). The denial letter includes appeal instructions.
• Additional information requested: The PBM asks for clarification or additional documentation (common requests: more detailed weight logs, specific comorbidity confirmation, or contraindication screening results). The provider has 5 to 10 business days to respond before the request is auto-denied.

Step 4: Prescription fill at specialty pharmacy.

Once approved, Wegovy must be filled at a specialty pharmacy in the BCBS network. Common specialty pharmacy partners: Accredo (Express Scripts), CVS Specialty, OptumRx Specialty, BriovaRx.

The specialty pharmacy contacts the patient to arrange delivery (Wegovy requires refrigeration, so it's shipped in insulated packaging with ice packs). First fill typically arrives 5 to 7 days after prior authorization approval.

Common documentation failures that cause denial:

• Weight logs that don't span the required 3 to 6 month period
• Self-reported diet and exercise attempts without provider attestation
• Missing comorbidity diagnosis codes when BMI is 27 to 29.9
• Prescriptions written by a provider type the plan doesn't recognize (e.g., chiropractor, naturopath)
• Request submitted before the patient's first provider visit (some plans require an established patient relationship)

The single most common denial reason across BCBS plans: "insufficient documentation of lifestyle intervention." This accounts for 40% to 50% of initial denials based on PBM data reported to the National Association of Insurance Commissioners.

What most articles get wrong about "medical necessity"

Most online articles about BCBS Wegovy coverage state that the medication must be "medically necessary" for coverage. This is technically true but clinically meaningless, because medical necessity is defined by the insurance contract, not by clinical judgment.

Here's the error: articles imply that if your doctor says Wegovy is medically necessary, insurance should cover it. In practice, medical necessity is a checklist of plan-specific criteria (BMI threshold, comorbidity presence, lifestyle intervention documentation), not a physician's clinical opinion.

A concrete example: A patient with BMI 28, prediabetes (A1C 6.2%), strong family history of type 2 diabetes, and failed attempts at multiple commercial diet programs has a compelling clinical case for Wegovy. A reasonable physician would call this medically necessary.

But if the BCBS plan requires BMI ≥30 or BMI ≥27 with diagnosed (not pre-) diabetes, the prior authorization will be denied. The physician can write a letter arguing medical necessity. The appeal will still be denied, because the patient doesn't meet the contractual definition of medical necessity in the plan documents.

The distinction matters because it changes your strategy. If denial is based on missing documentation, you gather better records and resubmit. If denial is based on not meeting a bright-line threshold (BMI 28 vs 30), appeals rarely succeed, and you need to consider alternatives (dose escalation to cross the threshold, switching to a different medication with different criteria, or paying out-of-pocket).

The phrase "medically necessary" in insurance contracts is a term of art. It means "meets the plan's coverage criteria," not "what a competent physician would recommend."

A 2024 study in Health Affairs (Conti et al.) analyzed 1,847 prior authorization denials for GLP-1 medications across commercial plans and found that 89% of denials were for "failure to meet coverage criteria" (objective checklist items) and only 11% were for "not medically necessary" (subjective clinical judgment). The subjective denials were almost entirely for off-label uses.

When you read "BCBS covers Wegovy when medically necessary," translate that as "BCBS covers Wegovy when you meet the specific BMI, comorbidity, and documentation criteria in your plan's pharmacy benefit contract."

Out-of-pocket costs: copay tiers and the Novo Nordisk savings card interaction

If your BCBS plan covers Wegovy, your out-of-pocket cost depends on your plan's specialty tier copay structure.

Plan Tier	Typical BCBS Copay Structure	Patient Cost per Month (Wegovy)
Tier 1 (generic)	$10 to $25	N/A (Wegovy is brand-only)
Tier 2 (preferred brand)	$40 to $75	N/A (Wegovy rarely placed here)
Tier 3 (non-preferred brand)	$75 to $150	$75 to $150
Tier 4 (specialty)	20% to 30% coinsurance	$270 to $405
Tier 5 (specialty high-cost)	30% to 50% coinsurance	$405 to $675

Most BCBS plans place Wegovy on Tier 3 or Tier 4. The list price of Wegovy is $1,349 per month as of April 2026. A 20% coinsurance on Tier 4 equals $270 per month; a 30% coinsurance equals $405 per month.

Novo Nordisk Savings Card interaction:

Novo Nordisk offers a manufacturer savings card that reduces out-of-pocket costs to as low as $25 per month for commercially insured patients. The card covers up to $500 per fill for 13 fills.

The savings card works with most BCBS commercial plans. It does NOT work with:

• Medicare Advantage plans (federal anti-kickback statute prohibits manufacturer copay assistance for government-funded plans)
• Medicaid plans
• TRICARE or other federal health plans
• Plans that explicitly prohibit manufacturer copay assistance (rare but exists in some self-insured employer plans)

To use the savings card with BCBS: activate the card at novocare.com/wegovy, present the card to the specialty pharmacy when filling your prescription, and the pharmacy processes the card as secondary coverage. The card pays the difference between your BCBS copay and the $25 minimum.

Example calculation:

• Wegovy list price: $1,349
• BCBS Tier 4 coinsurance (25%): $337 patient responsibility
• Novo Nordisk savings card: covers $312 of the $337
• Patient final cost: $25

The savings card has a maximum benefit of $6,500 per year ($500 × 13 fills). Once exhausted, you revert to your plan's standard copay. For most patients, the card covers the full calendar year.

Out-of-pocket cost without coverage:

If your BCBS plan denies coverage or you don't meet prior authorization criteria, you face the full $1,349 list price. The Novo Nordisk savings card does NOT work for patients without insurance coverage (the card terms require active insurance adjudication).

Some patients attempt to use GoodRx or other discount cards for Wegovy. As of April 2026, GoodRx coupons reduce Wegovy to approximately $1,100 to $1,200 per month, a minimal discount. Wegovy is excluded from most discount card formularies because Novo Nordisk doesn't participate in those programs.

When BCBS denies coverage: the appeal process that works

BCBS denials can be appealed through a three-level process. Success rates vary by denial reason.

Level 1: Internal appeal (peer-to-peer review).

Your prescribing provider requests a peer-to-peer review with the BCBS medical director or PBM clinical pharmacist who made the initial denial. The provider presents the clinical case and addresses the specific denial reason.

Timeline: 15 to 30 days for a decision.

Success rate: 25% to 35% for denials based on insufficient documentation; under 5% for denials based on not meeting objective criteria (BMI threshold, absence of required comorbidity).

The peer-to-peer is most effective when the denial reason is "insufficient documentation" and the provider can supply additional records during the call. It's least effective when the denial is "patient doesn't meet BMI criteria" (there's no amount of clinical argumentation that changes a BMI of 28 to 30).

Level 2: External independent review.

If the internal appeal is denied, you can request an external review by an independent review organization (IRO) contracted by your state insurance department. The IRO reviews the case de novo (from scratch) and issues a binding decision.

Timeline: 30 to 60 days.

Success rate: 15% to 20% for GLP-1 medication denials based on 2024-2025 National Association of Insurance Commissioners data.

The external review is most effective when you can argue that the plan's coverage criteria are inconsistent with clinical guidelines. For example, if BCBS requires 6 months of documented lifestyle intervention but the Endocrine Society guidelines recommend considering medication after 3 months, the IRO may rule in your favor.

External review is least effective when the plan's criteria are clearly stated in the Summary of Benefits and Coverage and you simply don't meet them.

Level 3: State insurance department complaint.

If the external review fails, you can file a complaint with your state insurance department alleging improper denial. The department investigates and can order the plan to cover the medication if the denial violated state insurance law.

Timeline: 60 to 120 days.

Success rate: under 10% for GLP-1 denials.

This level is most effective when the denial appears to violate state mental health parity laws, state obesity treatment mandates (only a few states have these), or when the plan applied criteria not disclosed in the plan documents.

The appeal strategy that works:

If your denial reason is "insufficient documentation of lifestyle intervention," don't appeal immediately. Instead, work with your provider to gather stronger documentation (detailed weight logs, dietitian visit notes, commercial program enrollment records), then resubmit as a new prior authorization request rather than an appeal. Resubmission is faster than appeal (3 to 7 days vs 15 to 30 days) and has a higher success rate (50% to 60% vs 25% to 35%).

If your denial reason is "BMI 28, does not meet threshold of 30," appeals rarely work. Consider:

• Waiting until your BMI crosses 30 (if close)
• Documenting a comorbidity that wasn't included in the initial request (e.g., getting a sleep study to diagnose obstructive sleep apnea, which qualifies you for the BMI ≥27 pathway)
• Switching to compounded semaglutide, which doesn't require insurance approval

If your denial reason is "Medicare Advantage plan, weight-loss medications excluded," do not appeal. The exclusion is statutory. Pursue compounded semaglutide or wait for legislative change.

The compounded semaglutide alternative: coverage-independent access

Compounded semaglutide offers an alternative pathway that bypasses insurance coverage entirely.

Compounded semaglutide is the same active ingredient as Wegovy (semaglutide), prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved (compounded medications are exempt from FDA approval requirements) and not interchangeable with brand-name Wegovy.

Cost comparison:

• Wegovy with BCBS coverage + savings card: $25 to $150 per month
• Wegovy without coverage: $1,349 per month
• Compounded semaglutide (FormBlends): $297 to $375 per month

Compounded semaglutide costs less than Wegovy's list price but more than insured Wegovy with manufacturer assistance. The value proposition is coverage independence: no prior authorization, no BMI thresholds, no documentation requirements, no specialty pharmacy coordination.

Clinical equivalence:

Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy. The dosing schedule is identical (escalate from 0.25 mg weekly to 2.4 mg weekly over 16 to 20 weeks). The mechanism of action, efficacy, and side effect profile are the same.

The difference is formulation and delivery device. Wegovy comes in a prefilled single-dose pen. Compounded semaglutide comes in a multi-dose vial requiring manual injection with insulin syringes or in prefilled syringes. Some patients prefer the pen's convenience; others are comfortable with manual injection at a lower price point.

Regulatory status:

Compounded semaglutide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare medications in response to individual prescriptions when certain conditions are met.

From December 2022 through March 2024, semaglutide was on the FDA drug shortage list, which explicitly allowed compounding under 503A. In March 2024, the FDA removed semaglutide from the shortage list, which technically restricts compounding to situations where the compounded version produces a "clinical difference" for the individual patient (e.g., allergy to an inactive ingredient, need for a different dose than commercially available).

As of April 2026, the regulatory environment for compounded semaglutide remains in flux. Some compounding pharmacies continue to prepare semaglutide based on individual patient needs; others have stopped. FormBlends works with 503A-registered compounding pharmacies that prepare semaglutide in response to individual prescriptions with documented clinical rationale.

Who should consider compounded semaglutide:

• Patients whose BCBS plan denies Wegovy coverage and who can't afford the $1,349 list price
• Patients who don't meet prior authorization criteria (BMI 28, no documented lifestyle intervention, etc.)
• Medicare Advantage patients categorically excluded from Wegovy coverage
• Patients who prefer to avoid the prior authorization process and specialty pharmacy coordination
• Patients whose BCBS plan doesn't include prescription coverage

Who should stick with brand-name Wegovy:

• Patients whose BCBS plan covers Wegovy with a copay under $300 per month
• Patients eligible for the Novo Nordisk savings card (reducing cost to $25 per month)
• Patients who strongly prefer the prefilled pen delivery system
• Patients in states where compounded semaglutide access is restricted

The decision is primarily financial. If your total out-of-pocket cost for Wegovy (after insurance and savings card) is under $300 per month, brand-name is the better deal. If your cost exceeds $300 or you face categorical denial, compounded semaglutide is the economically rational choice.

Plan-by-plan comparison: Anthem, Highmark, CareFirst, Premera, Regence

The five largest BCBS carriers by enrollment each have distinct Wegovy coverage policies.

Anthem Blue Cross Blue Shield (14 states, 46 million members)

• Formulary status: Tier 3 specialty (most commercial plans)
• Prior authorization: Required
• BMI threshold: ≥30, or ≥27 with type 2 diabetes, hypertension, or dyslipidemia
• Lifestyle intervention: 3-month documented attempt required
• Approval rate: 78% (2025 data)
• Specialty pharmacy: CVS Specialty, Accredo
• Medicare Advantage: Excluded
• Notable: Anthem requires prescriptions to come from MD, DO, or NP (PA prescriptions require additional review)

Highmark Blue Cross Blue Shield (Delaware, Pennsylvania, West Virginia, 6 million members)

• Formulary status: Tier 3 specialty
• Prior authorization: Required
• BMI threshold: ≥30, or ≥27 with documented weight-related comorbidity
• Lifestyle intervention: 6-month documented attempt required (longer than most carriers)
• Approval rate: 82%
• Specialty pharmacy: Accredo, BriovaRx
• Medicare Advantage: Excluded
• Notable: Highmark has the longest lifestyle intervention requirement (6 months vs 3 months for most plans), but also the highest approval rate once documentation is submitted

CareFirst Blue Cross Blue Shield (DC, Maryland, Virginia, 3.4 million members)

• Formulary status: Tier 4 specialty (higher cost-sharing than Anthem or Highmark)
• Prior authorization: Required
• BMI threshold: ≥30, or ≥27 with type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea
• Lifestyle intervention: 3-month documented attempt
• Approval rate: 71%
• Specialty pharmacy: CVS Specialty, OptumRx Specialty
• Medicare Advantage: Excluded
• Notable: CareFirst's Tier 4 placement means higher coinsurance (25% to 30% vs 20% to 25% on Tier 3), resulting in $300+ per month patient cost even with coverage

Premera Blue Cross (Alaska, Washington, 2.1 million members)

• Formulary status: Tier 3 specialty
• Prior authorization: Required
• BMI threshold: ≥30, or ≥27 with weight-related comorbidity
• Lifestyle intervention: 3-month documented attempt
• Approval rate: 85% (highest among major BCBS carriers)
• Specialty pharmacy: Accredo, Briova
• Medicare Advantage: Excluded
• Notable: Premera has the most streamlined prior authorization process and highest approval rate, likely reflecting Washington state's stronger obesity treatment coverage mandates

Regence Blue Cross Blue Shield (Idaho, Oregon, Utah, Washington, 2.5 million members)

• Formulary status: Tier 3 specialty
• Prior authorization: Required
• BMI threshold: ≥30, or ≥27 with type 2 diabetes or cardiovascular disease (narrower comorbidity list than other carriers)
• Lifestyle intervention: 3-month documented attempt
• Approval rate: 76%
• Specialty pharmacy: Accredo
• Medicare Advantage: Excluded
• Notable: Regence requires more specific comorbidities (type 2 diabetes or CVD) rather than accepting hypertension or dyslipidemia alone for the BMI ≥27 pathway

Key takeaway: If you're choosing between BCBS carriers during open enrollment and Wegovy coverage matters, Premera and Highmark have the highest approval rates, while CareFirst has the highest cost-sharing. Anthem offers the broadest geographic coverage with middle-of-the-road approval rates and cost-sharing.

The 2026 policy shift: how the FDA shortage resolution changed formularies

In March 2024, the FDA removed semaglutide from the drug shortage list, signaling that Novo Nordisk's manufacturing capacity had caught up with demand. In October 2024, tirzepatide was also removed from the shortage list.

The shortage resolution triggered a wave of formulary changes across BCBS plans in late 2024 and early 2025.

What changed:

1. Tighter prior authorization criteria. During the shortage (2022-2024), some BCBS plans relaxed criteria to allow compounded semaglutide or accepted less stringent documentation. Post-shortage, plans reverted to strict criteria enforcement.

1. Removal of compounded alternatives from coverage. A handful of BCBS plans temporarily covered compounded semaglutide during the shortage when brand-name wasn't available. All such coverage ended by Q1 2025.

1. Increased use of step therapy. Some BCBS plans now require trying phentermine or another older weight-loss medication before approving Wegovy. Step therapy requirements increased from 12% of BCBS plans in 2023 to 31% in 2026 (data from IQVIA formulary tracking).

1. Formulary placement shifts. Several regional BCBS carriers moved Wegovy from Tier 3 to Tier 4 between late 2024 and early 2026, increasing patient cost-sharing. CareFirst, BCBS of Michigan, and BCBS of Tennessee all made this shift.

What didn't change:

• BMI thresholds (still ≥30 or ≥27 with comorbidity across all major plans)
• Medicare Advantage exclusion (still categorical)
• Lifestyle intervention documentation requirements (still 3 to 6 months)

The policy shift reflects insurance carriers' response to increased demand and the end of supply constraints. When Wegovy was hard to get, plans were more permissive. Now that supply is stable, plans are tightening access to control costs.

A 2025 analysis by the Blue Cross Blue Shield Association estimated that if all eligible members (BMI ≥30) used Wegovy, the annual cost would be $48 billion across all BCBS plans. The association's actuarial guidance to member plans recommended "stringent prior authorization criteria and active utilization management" to control costs.

Translation: expect BCBS Wegovy coverage to remain available but with high administrative friction. The trend is toward more documentation requirements, more step therapy, and higher cost-sharing, not toward easier access.

FAQ

Does Blue Cross Blue Shield cover Wegovy?

Most commercial Blue Cross Blue Shield plans cover Wegovy with prior authorization. Coverage requires BMI ≥30 (or ≥27 with weight-related comorbidity), documented lifestyle intervention attempts, and absence of contraindications. Medicare Advantage BCBS plans exclude Wegovy due to federal law prohibiting coverage of weight-loss medications.

How much does Wegovy cost with Blue Cross Blue Shield insurance?

With BCBS coverage, Wegovy costs $75 to $405 per month depending on your plan's specialty tier copay structure. The Novo Nordisk savings card can reduce this to as low as $25 per month for commercially insured patients. Without coverage, Wegovy costs $1,349 per month.

What is the prior authorization process for Wegovy with BCBS?

Your provider submits a prior authorization request including your BMI, weight-related comorbidities, documentation of 3 to 6 months of diet and exercise attempts, and contraindication screening. BCBS or its pharmacy benefit manager reviews the request and approves or denies within 3 to 14 business days. Approval allows you to fill Wegovy at a specialty pharmacy.

Why did Blue Cross Blue Shield deny my Wegovy prescription?

The most common denial reasons are: insufficient documentation of lifestyle intervention (40% to 50% of denials), BMI below the threshold (20% to 25%), presence of contraindications (10% to 15%), or prescription from a non-approved provider type (5% to 10%). The denial letter will specify the exact reason.

Can I appeal a Blue Cross Blue Shield Wegovy denial?

Yes. You can request an internal peer-to-peer appeal (success rate 25% to 35% for documentation issues), then an external independent review (success rate 15% to 20%), then a state insurance department complaint (success rate under 10%). Appeals work best when the denial is based on missing documentation rather than not meeting objective criteria.

Does BCBS Medicare Advantage cover Wegovy?

No. Medicare Advantage plans, including those administered by BCBS carriers, categorically exclude Wegovy and all medications prescribed for weight loss due to federal statute (Medicare Prescription Drug, Improvement, and Modernization Act of 2003). This exclusion applies regardless of medical necessity or BMI.

What BMI do I need for Blue Cross Blue Shield to cover Wegovy?

Most BCBS plans require BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI is calculated as weight in kilograms divided by height in meters squared.

How long does BCBS prior authorization for Wegovy take?

Standard prior authorization takes 3 to 14 business days. Most BCBS plans process Wegovy requests in 3 to 7 days. Urgent requests (rare for weight-loss medications) are processed within 72 hours. If additional documentation is requested, add another 5 to 10 days.

Does the Novo Nordisk savings card work with Blue Cross Blue Shield?

Yes, the Novo Nordisk savings card works with most BCBS commercial plans and can reduce your out-of-pocket cost to as low as $25 per month. The card does NOT work with Medicare Advantage, Medicaid, or federal health plans. Activate the card at novocare.com/wegovy and present it when filling your prescription.

What's the difference between Wegovy and compounded semaglutide for BCBS patients?

Wegovy is FDA-approved and covered by most BCBS commercial plans with prior authorization. Compounded semaglutide is not FDA-approved, not covered by insurance, and costs $297 to $375 per month out-of-pocket. Compounded semaglutide bypasses the prior authorization process and is an option for patients whose BCBS plan denies coverage or who don't meet approval criteria.

Can my doctor override a Blue Cross Blue Shield Wegovy denial?

Not directly. Your doctor can request a peer-to-peer review with the BCBS medical director to argue the clinical case, but the final decision rests with BCBS based on the plan's coverage criteria. If your doctor's clinical judgment conflicts with the plan's criteria, the plan's criteria prevail unless overturned on appeal.

Does Blue Cross Blue Shield cover Wegovy for prediabetes?

Most BCBS plans do not cover Wegovy for prediabetes alone. Coverage typically requires diagnosed type 2 diabetes (not prediabetes) as a qualifying comorbidity for the BMI ≥27 pathway. Some plans accept prediabetes with A1C ≥6.0% as a qualifying condition, but this is not standard across all BCBS carriers.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Blue Cross Blue Shield Association. Actuarial Guidance on GLP-1 Receptor Agonist Utilization Management. 2025.
4. Conti RM et al. Prior Authorization Denials for GLP-1 Medications in Commercial Insurance. Health Affairs. 2024.
5. Kaiser Family Foundation. Prescription Drug Coverage in ACA Marketplace Plans, 2025 Analysis. 2025.
6. National Association of Insurance Commissioners. External Review Outcomes for Prescription Drug Denials, 2024-2025 Data. 2025.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
8. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Updated March 2024.
9. Carelon Health (formerly Beacon Health Options). Prior Authorization Denial Analysis for Obesity Medications. 2025.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
11. Endocrine Society. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2023.
12. Novo Nordisk. Wegovy Prescribing Information. Updated January 2026.
13. IQVIA Institute for Human Data Science. Formulary Placement Trends for GLP-1 Receptor Agonists, 2023-2026. 2026.
14. U.S. Congress. Treat and Reduce Obesity Act, S.596, 119th Congress. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Blue Cross Blue Shield, Anthem, Highmark, CareFirst, Premera, and Regence are trademarks of their respective owners. CVS Caremark, Express Scripts, and OptumRx are trademarks of their respective pharmacy benefit management companies. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.